BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026

BPM31510 for GBM at ASCO 2026

BPM31510 is a first-in-class therapeutic targeting tumor metabolism to re-program mitochondrial microenvironment in Warburg-avid tumors•Both safety profile and efficacy data to be highlighted in methylated and unmethylated GBM tumors

Format

PNG

Source

BPGbio

Downloads